Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sleep therapy may protect hearts of PTSD patients

NCT ID NCT04498754

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether treating insomnia can reduce the risk of heart disease in people with PTSD. Researchers measured blood pressure, blood vessel health, and other heart risk factors in 140 adults aged 40-59. The goal was to see if improving sleep could also improve heart health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Mar 2021

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is between 40-59 years old; * Has a current diagnosis of chronic PTSD (at least 3 months duration) based on the Clinician Administered PTSD Scale DSM-5 version (Weathers et al., 2013); * Has a current diagnosis of ID as defined in the International Classification of Sleep Disorders (ICSD-3; American Academy of Sleep Medicine, 2014) Exclusion Criteria: * Has a history of CVD events, including myocardial infarction, stroke, transient ischemic attack, or coronary revascularization; * Has diagnosis of congestive heart failure or coronary artery disease based on results of diagnostic testing; * Has a current alcohol use or substance use disorder (those who meet lifetime but not current alcohol or substance use disorder will be included); * Is currently participating in or has recently (past 6 months) participated in an evidence-based trauma focused therapy for PTSD; * Has cognitive impairment as evidenced by less than 20 on the Montreal Cognitive Assessment scale (M0CA; Nasreddine et al., 2005); * Meets criteria for a psychotic spectrum disorder or bipolar disorder; * Has severely impaired hearing or speech; * Is pregnant; * Does not use benzodiazepines for sleep, and if prescribed benzodiazepines for some other use (e.g., anxiety, panic attacks), uses them fewer than four times in a one month period.; * Is not stable (medications and dose stable for one month) on any other current psychoactive and/or cardiovascular medications or will not be stable on these medications during the course of the study; * Works night shift; * Is participating in another interventional study to address insomnia; * Has prominent suicidal or homicidal ideation (as assessed through a clinical interview); * Has a serious/terminal illness or other health problem that would prohibit participation in the study; * Has nonclinically significant or sub-threshold insomnia as indicated by a score of \<8 on the Insomnia Severity Index; * Has seizures (based on clinical interview and self-report); * Has a body mass index of 45 or greater; * Has sleep apnea (based on the overnight assessment described below) or a positive sleep apnea screen; * Has restless leg syndrome (based on the Duke Structured Interview for Sleep Disorders (DSISD); Edinger, Wyatt, \& Olsen, 2009), and that sleep disorder is the primary cause of their sleep complaint (participants with restless legs syndrome who also have insomnia disorder can be included in the study); * Has an organic cause of sleep disruption that cannot be addressed by cognitive-behavioral changes (e.g., hyperthyroidism), as determined by the DSISD; * Has excessive daytime sleepiness, defined as a score \>15 on the Epworth Sleepiness Scale (ESS) or as determined by the DSISD; * Does not complete sleep diary assessments within 6 hours of rising on at least 5 of the 7 days of the initial assessment period; or * Cancels or no-shows for two or more Time 1 assessment appointments * Has uncontrolled hypertension (screening office BP \> 160/100 mm Hg)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular risk factor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27706, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.